Company news

Halozyme Therapeutics, Inc. news in 2021

Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Halozyme appoints new general counsel

December 12, 2021

Halozyme announces $750 million three-year share repurchase program

December 8, 2021

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

November 30, 2021

Halozyme Reports Third Quarter 2021 Results

November 1, 2021

Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call

October 18, 2021

Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference

September 14, 2021

Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference

August 25, 2021

Halozyme Reports Second Quarter 2021 Results

August 8, 2021

Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference

July 29, 2021

Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call

July 26, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV

June 21, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV

June 21, 2021

Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma

June 21, 2021

Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2021

Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®

May 20, 2021

Halozyme Reports First Quarter 2021 Results

May 9, 2021

Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference

April 28, 2021

Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call

April 19, 2021

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027

February 23, 2021

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027

February 22, 2021

Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results

February 22, 2021

Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call

February 9, 2021

Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis

January 14, 2021

Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth

January 10, 2021

Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference

January 3, 2021

Calls in 2021

Decks in 2021